JP2024539079A - Ｈｅｒ２バリアントｃａｒ - Google Patents

Ｈｅｒ２バリアントｃａｒ Download PDF

Info

Publication number
JP2024539079A
JP2024539079A JP2024523266A JP2024523266A JP2024539079A JP 2024539079 A JP2024539079 A JP 2024539079A JP 2024523266 A JP2024523266 A JP 2024523266A JP 2024523266 A JP2024523266 A JP 2024523266A JP 2024539079 A JP2024539079 A JP 2024539079A
Authority
JP
Japan
Prior art keywords
p95her2
seq
cells
car
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539079A5 (enExample
Inventor
アムンド カイト、ヨン
ドラージ、エス．エスマエイル
Original Assignee
オスロ ユニヴェルジテットサイケフス ホーエフ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by オスロ ユニヴェルジテットサイケフス ホーエフ filed Critical オスロ ユニヴェルジテットサイケフス ホーエフ
Publication of JP2024539079A publication Critical patent/JP2024539079A/ja
Publication of JP2024539079A5 publication Critical patent/JP2024539079A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57575—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
JP2024523266A 2021-10-19 2022-10-19 Ｈｅｒ２バリアントｃａｒ Pending JP2024539079A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2114938.0A GB202114938D0 (en) 2021-10-19 2021-10-19 Her2 variant car
GB2114938.0 2021-10-19
PCT/EP2022/079110 WO2023067007A1 (en) 2021-10-19 2022-10-19 Her2 variant car

Publications (2)

Publication Number Publication Date
JP2024539079A true JP2024539079A (ja) 2024-10-28
JP2024539079A5 JP2024539079A5 (enExample) 2025-10-10

Family

ID=78718395

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523266A Pending JP2024539079A (ja) 2021-10-19 2022-10-19 Ｈｅｒ２バリアントｃａｒ

Country Status (7)

Country Link
US (1) US20240398949A1 (enExample)
EP (1) EP4419133A1 (enExample)
JP (1) JP2024539079A (enExample)
KR (1) KR20240099303A (enExample)
CN (1) CN118382455A (enExample)
GB (1) GB202114938D0 (enExample)
WO (1) WO2023067007A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025147472A1 (en) * 2024-01-02 2025-07-10 Phanes Therapeutics, Inc. Anti-611-ctf p95her2 antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100143927A1 (en) * 2008-12-01 2010-06-10 Jeff Sperinde Methods and Assays for Measuring p95 and/or p95 in a Sample and Antibodies Specific for p95
JP2011525175A (ja) * 2008-06-02 2011-09-15 フンダシオ プリバーダ インスティトゥト デ レセルカ ホスピタル ウニベルシタリ バル ヘブロン Ｈｅｒ２受容体またはその末端切断変異体を発現する癌を診断するための方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5972871B2 (ja) * 2010-07-20 2016-08-17 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｉｌ−２３ヘテロ二量体特異的抗体
WO2020075325A1 (ja) * 2018-10-09 2020-04-16 公立大学法人福島県立医科大学 子宮体癌患者の予後予測バイオマーカー
EP3915576A1 (en) * 2020-05-28 2021-12-01 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Chimeric antigen receptors specific for p95her2 and uses thereof
AU2023282410A1 (en) * 2022-06-07 2024-12-05 Duality Biologics (Suzhou) Co., Ltd. Anti-b7h3 antibody-drug conjugate and use thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011525175A (ja) * 2008-06-02 2011-09-15 フンダシオ プリバーダ インスティトゥト デ レセルカ ホスピタル ウニベルシタリ バル ヘブロン Ｈｅｒ２受容体またはその末端切断変異体を発現する癌を診断するための方法
US20100143927A1 (en) * 2008-12-01 2010-06-10 Jeff Sperinde Methods and Assays for Measuring p95 and/or p95 in a Sample and Antibodies Specific for p95

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCERS, vol. 14, no. 4859, JPN6026022429, 5 October 2022 (2022-10-05), pages 1 - 24, ISSN: 0005875768 *
CLINICAL CANCER RESEARCH, vol. 16(16), JPN6026022428, 2010, pages 4226 - 4235, ISSN: 0005875767 *
SCIENCE TRANSLATIONAL MEDICINE, vol. 10(461), JPN6026022427, 2018, ISSN: 0005875766 *

Also Published As

Publication number Publication date
KR20240099303A (ko) 2024-06-28
CN118382455A (zh) 2024-07-23
WO2023067007A1 (en) 2023-04-27
GB202114938D0 (en) 2021-12-01
US20240398949A1 (en) 2024-12-05
EP4419133A1 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
US12325759B2 (en) Anti-VEGF-anti-PD-L1 bispecific antibody, pharmaceutical composition of same, and uses thereof
JP7564991B2 (ja) Ｓｅｍａ４ｄ抗体及びその製造方法と使用
JP6307085B2 (ja) メソテリン抗体および強力な抗腫瘍活性を惹起するための方法
TWI812645B (zh) 新型抗cd19抗體
US20220017615A1 (en) Cd47 antibody, preparation method therefor and uses thereof
JP2018035137A (ja) 新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
AU2015249887A1 (en) Novel anti-RNF43 antibodies and methods of use
RS58352B1 (sr) Multivalentni antigen-vezujući fv molekul
TWI825459B (zh) 一種SIRPα-Fc融合蛋白
JP2018523487A (ja) 抗コチニン抗体が連結したキメラ抗原受容体およびその使用
WO2023143315A1 (zh) 一种靶向ror1的抗体或其抗原结合片段及其应用
CN113166251A (zh) 抗人tim-3单克隆抗体及其应用
US20240398949A1 (en) Her2 variant car
JP2025535040A (ja) 抗ウロキナーゼ型プラスミノーゲン活性化因子受容体抗体及び使用方法
IL315506A (en) ROR-1 binding molecule and its use
JP2025525538A (ja) 抗ｒｏｒ１抗体、これを含む二重特異性抗体、およびこれらの用途
KR20240006506A (ko) 항-백시니아 바이러스 항원 항체 및 관련 조성물 및 방법
WO2024223835A1 (en) Binding molceule against p95 her2 variants
EP4567046A1 (en) Antibody targeting egfrviii and use thereof in cell immunotherapy
RU2791445C2 (ru) Новые анти-cd19-антитела
CN116769036A (zh) 5t4全人源单克隆抗体及其应用
CA3254345A1 (en) Ror1-targeted binding molecule and use thereof
BR122025029428A2 (pt) Anticorpo isolado anti-cd19, sequências de polinucleotídeo isolado e de ácido nucleico, vetores, célula hospedeira, método de expressar o anticorpo, conjugado anticorpo-droga, composição farmacêutica, uso do anticorpo, receptor de antígeno quimérico (car), célula t isolada, método para estimular uma resposta imune, e kit

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251002

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251002

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260602